Summary
Pfizer Inc.'s 2018 10-K filing highlights a year of strategic transformation and ongoing business development. A significant event for investors is the announced agreement to combine its consumer healthcare business with GSK's, forming a joint venture where Pfizer will hold a 32% equity stake. This move signals a strategic pivot, shifting focus towards its biopharmaceutical core. The company operated under a dual-segment structure (Innovative Health and Essential Health) throughout 2018, but is transitioning to a new three-business global structure (Biopharmaceuticals Group, Upjohn, and Consumer Healthcare) starting in 2019. This reorganization aims to capitalize on evolving market dynamics and drive future growth. Key operational areas include the biopharmaceutical group, focusing on novel medicines and vaccines across critical therapeutic areas like oncology, inflammation & immunology, and rare diseases, alongside a new hospital business unit. The Upjohn segment addresses off-patent established medicines, primarily in China. The filing also details significant R&D efforts and a robust pipeline, though it acknowledges the inherent risks and costs associated with drug development and the competitive landscape. Investors should note the company's significant international revenue contribution, which exposes it to currency fluctuations and varying regulatory environments.
Financial Highlights
56 data points| Revenue | $40.83B |
| Cost of Revenue | $8.99B |
| Gross Profit | $31.84B |
| SG&A Expenses | $12.61B |
| Operating Income | $3.83B |
| Interest Expense | $1.32B |
| Net Income | $11.15B |
| EPS (Basic) | $1.90 |
| EPS (Diluted) | $1.87 |
| Shares Outstanding (Basic) | 5.87B |
| Shares Outstanding (Diluted) | 5.98B |
Key Highlights
- 1Pfizer announced an agreement to combine its consumer healthcare business with GSK's into a new global joint venture, with Pfizer retaining a 32% equity stake.
- 2The company is reorganizing its commercial operations into three distinct businesses effective 2019: Pfizer Biopharmaceuticals Group, Upjohn, and Consumer Healthcare.
- 3Pfizer's business segments for 2018 were Pfizer Innovative Health (IH) and Pfizer Essential Health (EH), with IH focusing on novel therapies and EH on established, off-patent medicines.
- 4Significant investments in Research and Development (R&D) are noted, with a focus on therapeutic areas like Oncology, Inflammation & Immunology, Rare Diseases, and Vaccines.
- 5International operations are a substantial part of Pfizer's business, accounting for 53% of total revenues in 2018, highlighting exposure to global economic and regulatory factors.
- 6The company actively engages in business development, including alliances, licenses, joint ventures, and acquisitions, to drive growth and enhance shareholder value.
- 7Patent expirations and the increasing threat of generic and biosimilar competition are identified as key risks impacting revenue for several major products.